Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001–2009)

التفاصيل البيبلوغرافية
العنوان: Use of first- and second-generation antipsychotic medications in older patients with schizophrenia in Asia (2001–2009)
المؤلفون: Ee Heok Kua, Senta Fujii, Mian-Yoon Chong, Julie Kreyenbuhl, Gabor S. Ungvari, Eun Kee Chung, Naotaka Shinfuku, Faith Dickerson, Kang Sim, Helen F.K. Chiu, Chay Hoon Tan, Michael K. Yong, Shu Yu Yang, Chuanyue Wang, Pichet Udomratn, Jitendra K. Trivedi, Norman Sartorius, Tian-Mei Si, Kok Yoon Chee, Yanling He, Yu-Tao Xiang, Edwin Ho Ming Lee
المصدر: Australian & New Zealand Journal of Psychiatry. 46:1159-1164
بيانات النشر: SAGE Publications, 2012.
سنة النشر: 2012
مصطلحات موضوعية: Male, Health Knowledge, Attitudes, Practice, medicine.medical_specialty, Asia, Hospitalized patients, medicine.medical_treatment, Older patients, medicine, Haloperidol, Asian country, Adverse Drug Reaction Reporting Systems, Humans, Practice Patterns, Physicians', Medical prescription, Psychiatry, Antipsychotic, Aged, Demography, Dose-Response Relationship, Drug, business.industry, General Medicine, medicine.disease, Hospitalization, Psychiatry and Mental health, Cross-Sectional Studies, Socioeconomic Factors, Schizophrenia, Female, Antipsychotic Medications, Health Impact Assessment, business, Antipsychotic Agents, medicine.drug
الوصف: Objective: This study examined the prescribing patterns of several first- (FGAs) and second-generation antipsychotic (SGAs) medications administered to older Asian patients with schizophrenia during the period between 2001 and 2009. Method: Information on hospitalized patients with schizophrenia aged 65 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001–2009). There were no older patients in Thailand, therefore data on 467 patients in eight Asian countries and territories including China, Hong Kong SAR, India, Japan, Korea, Malaysia, Singapore, and Taiwan were analysed. Cross-sectional socio-demographic data, clinical characteristics and antipsychotic prescriptions were assessed using a standardized protocol and data collection procedure. Results: Of the 467 patients, 192 patients (41.1%) received FGAs only, 166 (35.5%) received SGAs only and 109 (23.3%) received a combination of FGAs and SGAs. Of the FGAs, haloperidol was the most commonly used (31.3%; mean 9.4 ± 6.7 mg/day), followed by chlorpromazine (15.4%; mean 126.4 ± 156.4 mg/day) and sulpiride (6.6%; mean 375.0 ± 287.0 mg/day). Of the SGAs, risperidone was the most commonly used (31.5%; mean 4.5 ± 2.7 mg/day), followed by olanzapine (13.1%; mean 13.6 ± 6.5 mg/day), quetiapine (7.3%; mean 325.0 ± 237.3 mg/day) and aripiprazole (1.9%; mean 17.6 ± 7.7 mg/day). Conclusions: FGAs and higher doses of certain SGAs (risperidone, olanzapine and quetiapine) were still commonly dispensed to older Asian patients with schizophrenia. Considering older patients’ reduced tolerability of potentially severe side effects associated with FGAs and higher doses of certain SGAs, continuing education and training addressing the rational use of antipsychotics in this population is clearly needed.
تدمد: 1440-1614
0004-8674
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f07488e9fc4db5ee337dc0b2fb3cf90bTest
https://doi.org/10.1177/0004867412453625Test
حقوق: CLOSED
رقم الانضمام: edsair.doi.dedup.....f07488e9fc4db5ee337dc0b2fb3cf90b
قاعدة البيانات: OpenAIRE